中国临床药理学杂志Issue(23)：2281-2283,3.DOI:10.13699/j.cnki.1001-6821.2015.23.001
恩替卡韦联合聚乙二醇干扰素α－2a治疗慢性乙型病毒性肝炎的临床疗效及安全性
Clinical efficacy and safety of entecavir combined with peginterferon α-2a in the treatment of chronic hepatitis B
摘要
Abstract
Objective To evaluate the clinical efficacy and safety of entecavir joint peginterferon α-2 a in the treatment of chronic hepatitis B.Methods The 80 cases of chronic hepatitis B patients were randomly divided into control group ( n =40 ) and treatment group ( n =40 ) . Patients in control group were given peginterferonα-2a 0.5 mL, once a week.Patients in treatment group were plused with oral entecavir 0.5 mg on the basis of control group, once a day.A course of treatment was a month in two groups, 12 courses of treatment. Respectively in the treatment of 3, 6, 12 months and 6 months after treatment, the hepatitis B virus ( HBV) DNA negative rate and alanine aminotransferase ( ALT) normalization rate of two groups were tested.After treatment, the clinical efficacy and incidence of adverse drug reactions of the two groups were compared.Results After treatment, the total effective rate of treatment group was significantly higher than that of control group ( 92.50% vs 67.50%, P<0.05).The treatment of 3, 6, 12 months and 6 months after treatment,the HBV DNA negative rate and ALT normalization rate of treatment group were significantly higher than those of control group (P<0.05).Adverse drug reactions in two groups had no significant difference (P>0.05).Conclusion Entecavir combined with peginterferonα-2a in the treatment of chronic hepati-tis B had distinct clinical efficacy and good safety.关键词
恩替卡韦/慢性乙型病毒性肝炎/乙型病毒性肝炎e抗原阳性/聚乙二醇干扰素α-2aKey words
entecavir/chronic hepatitis B/hepatitis Beantigen positive/peginterferon α-2 a分类
医药卫生引用本文复制引用
聂尚燕,赵蕾,麻慧宇,宋欢欢,王敏,卢力飞..恩替卡韦联合聚乙二醇干扰素α－2a治疗慢性乙型病毒性肝炎的临床疗效及安全性[J].中国临床药理学杂志,2015,(23):2281-2283,3.基金项目
河北省邯郸市科技局科技支撑基金资助项目 （）
